三生制药
3SBIO INC.

2022 Interim Results Presentation

August 25, 2022

Disclaimer

This document has been prepared by 3SBio Inc. (the "Company") solely for selected recipients for information purposes only.

You must read the terms, conditions, limitations, notifications, restrictions, acknowledgments and representations in the following (collectively, the "Terms") before reading or making any other use of this document. In accepting the delivery of, reading or making any other use of this document, you acknowledge and agree to be bound by the Terms, and you agree to maintain absolute confidentiality regarding the information disclosed in this document in a manner consistent with the Terms. If you do not accept any of the Terms, in whole or in part, please immediately return this document to the Company.

These materials, and any further information made available to you, are highly confidential and are being given solely for your information. These materials, and any further information made available to you, form part of the proprietary information of the Company and may not be copied, reproduced, redistributed or passed on, directly or indirectly, to any other person (whether within or outside your organization/firm) or published or otherwise disclosed, in whole or in part, in any manner and for any purpose without the prior written consent from the Company. Any forwarding, distribution or reproduction of this document, in whole or in part, is unauthorized.

The information used in preparing this document has not been independently verified and has not been reviewed by any regulatory authority in any jurisdiction. This document does not purport to provide a complete description of the matters to which it relates. No representation, warranty or undertaking, express or implied, is or will be made or given by, and no responsibility or liability is or will be accepted by, any person (for the avoidance of doubt, including but not limited to, the Company and its affiliates, controlling persons, shareholders, directors, officers, partners, employees, agents, representatives or advisers of any of the foregoing), with respect to the accuracy, reliability, correctness, fairness or completeness of this document or its contents or any oral or written communication in connection with this document. In addition, any analyses included herein are not and do not purport to be complete or comprehensive and are not and do not purport to be appraisals of the assets, stock or business of the Company or any of its holding companies, subsidiaries or other affiliates. Even when these materials contain a form of appraisal, it should be considered as preliminary, suitable only for the purpose described herein, subject to assumptions and not be disclosed or otherwise used without the prior written consent of the Company. The information in this document does not take into account the effects of a possible transaction or certain transactions which may have significant valuation and other effects. Nothing contained in this document is, or shall be, relied upon as a promise or representation as to the future or as a representation or warranty otherwise.

Nothing in this document constitutes or forms part of, or should be construed as constituting or forming part of, any regulatory, valuation, legal, tax, accounting, investment, or other advice. Nothing in this document constitutes or forms part of, or should be construed as constituting or forming part of, any recommendation, solicitation, offer or commitment to purchase, sell, subscribe for or underwrite any securities by any party, or to extend any credit or provide any insurance to you or to enter into any transaction, nor shall there be any sale of securities or other transaction in any jurisdiction in which such sale or transaction would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Unless otherwise agreed in writing, any third party from whom you receive this document is not acting as your financial adviser or fiduciary. Before you enter into any transaction, you should ensure that you fully understand the potential risks and rewards of that transaction and you should consult with such advisers as you deem necessary to assist you in making these determinations, including, but not limited to, your accountants, investment advisors and legal and/or tax experts. None of the Company and its affiliates, controlling persons, shareholders, directors, officers, partners, employees, agents, representatives or advisers of any of the foregoing shall have any liability (in negligence or otherwise) in respect of the use of, or reliance upon, the information contained herein by you or any person to whom the information herein is disclosed.

The contents of this document are subject to corrections or changes at any time without further notice. The information contained in these materials also contains certain forward-looking statements regarding the Company's intent, plans, beliefs, strategies, and growth prospects as well as the projected growth of China's economy and the pharmaceutical industry, which are based on various assumptions and subject to risks and uncertainties. In light of these assumptions, risks, and uncertainties, the future facts, events and circumstances described in these materials may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. The forward-looking statements are not guarantees of future performance. Each of the Company and its and its affiliates, controlling persons, shareholders, directors, officers, partners, employees, agents, representatives or advisers of any of the foregoing assumes no obligation to (1) provide access to any additional information, (2) correct any mistakes or inaccuracies in this document, or (3) update or otherwise revise this document, for any reason whatsoever, including without limitation to reflect new information, events or circumstances that arise, occur or become known after the date of this document.

By receiving or reading this document, you acknowledge and represent to the Company and its affiliates, controlling persons, shareholders, directors, officers, partners, employees, agents, representatives or advisors that (1) you are a "professional investor" as defined in the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and the rules made thereunder, have the knowledge and experience in financial and business matters, and are capable of evaluating the merits and risks of and conducting your own assessment of the Company and its shares, (2) you are a person into whose possession this document may lawfully be delivered in accordance with the laws of the jurisdiction in which you are located, and (3) you have conducted and will conduct your own investigation with respect to the Company and its shares and have obtained or will obtain your own independent advice relating to the investment in the shares of the Company, and, if located in the United States, are either a "qualified institutional buyer" or an institutional "accredited investor" as defined in the U.S. Securities Act of 1933, as amended, and the regulations enacted thereunder (the "U.S. Securities Act").

No information set out in this document will form the basis of or be relied upon in connection with any contract, commitment or investment decision. Any prospective investor will be required to acknowledge in any purchase contract that it has not relied on, or been induced to enter into such agreement by, any representation or warranty, save as expressly set out in such agreement. This document does not constitute, in whole or in part, an offer or invitation for the sale, purchase or subscription of any security. Any such offer or invitation will be made solely through a prospectus or offering circular in compliance with all applicable laws and any decision to purchase or subscribe for any security should be made solely on the basis of the information contained in such prospectus or offering circular issued in connection with such offer or invitation.

This document contains no information or material which may result in it being deemed (1) to be a prospectus within the meaning of the U.S. Securities Act; (2) to be a prospectus within the meaning of section 2(1) of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong), or an advertisement in relation to a prospectus or proposed prospectus or extract from or abridged version of a prospectus within the meaning of section 38B of the Companies (Winding Up and Miscellaneous Provisions) Ordinance or an advertisement, invitation or document containing an advertisement or invitation falling within the meaning of section 103 of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) or (3) to have effected an offer to the public in the United States, Hong Kong or anywhere else without compliance with all applicable laws and regulations or being able to invoke any exemption available under all applicable laws and regulations and is subject to material change without notice. The distribution of this document may be restricted by law, and persons into whose possession this document comes should inform themselves of, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the applicable securities laws. The Company does not intend to conduct any public offering of securities in the United States, Hong Kong or anywhere else.

Agenda

01 2022H1 Highlights

02 Business Overview

03 R&D

04 Financial Review

05 Q&A

01
Highlights

Business Overview

R&D

Q&A

Financial Review

Chairman, Director & CEO

Dr. Jing LOU

2022H1 Financial Highlights

Main Performance (RMB million)	2022H1	2021H1	YoY
Revenue	3091.4	3,107.1	-0.5%
Gross Profit	2565.0	2,587.1	-0.9%
NI Attributable to Parent	954.5	898.9	6.2%
Norm NI Attributable to Parent	993.6	929.8	6.9%
Equity Attributable to Parent	12,047.6	12,227.5	-1.5%
EPS (HKD)	0.46	0.42	11.4%

Income proportions：





2022H1 Highlights

2022.01 The global rights of PD-1 on specific therapy were authorized to U.S. Syncromune Inc.

2022.01 Mandi Foam NDA was accepted for review

2022.05 Phase III clinical study of TPIAO in pediatric ITP achieved the pre-defined primary endpoint



2022.05 During the outbreak of COVID-19, 400+ staff resided in the factory for production, CDMO orders from customers were 100% delivered on a schedule

2022.06 Mandi “618” E-commercial sales revenue set a new record

2022.06 The ADC development and global commercialized rights of Cipterbin were authorized to Kelingyuan

2022.06 Phase II clinical study of anti-IL17A mAb(608) in PsO achieved the primary endpoint

2022.07 Partnered with Cosmo and received the exclusive right to develop and commercialize cream Winlevi® to treat acne in Greater China and the right of first refusal of Breezula® solution to treat alopecia

Biopharmaceuticals

Hair Healthcare

CDMO

R&D

Highlights

R&D

02

Business Overview

Q&A

Financial Review

Chairman, Director & CEO

Dr. Jing LOU

Business Ⅰ: Biopharmaceuticals

Core Products

Revenue of Core Products, 2022H1

RMB million



Product		Growth rate
TPIAO		3.5%
rhEPO		-1.9%
Yisaipu		-45.5%
Cipterbin		111.6%
Mandi		42.0%

TPIAO- Exclusive Commercialized rhTPO

Revenue of TPIAO, 2022H1

RMB million

1 **Top 1 market share**

66% [1] market share in terms of sales, still tops the first position in rhTPO products



1.Data source： IQVIA Jan-Jun, 2022， Total market volume includes TPO, interleukin-11 and Eltrombopag

TPIAO- Distinct Space for Stable Growth

Persistent Replacement and Penetration

- The number of hospitals covered>4000
- 27%[1] of penetration rate in thrombocytopenia market measured by sales volume



Full Course Management

- Chemotherapy-induced Thrombocytopenia (CIT) was expanded to Cancer Treatment Induced Thrombocytopenia (CTIT) [2]



Anticipated Indication Expansion

- Pediatric ITP: 13K patients /year[3], prepared to NDA submission
- CLDT: 350K+ patients /year[4] , Phase II patient enrollment has been completed, Est. 2025 NDA



1.Data source: IQVIA Jan-Jun, 2022, Total market volume includes TPO, interleukin-11 and Eltrombopag
2. "Guidelines for CSCO Cancer Therapy Induced Thrombocytopenia (2022)"
3. Data source: pediatric ITP treatment guidelines
4. Data source: Libing, chenguofeng, Reasons for CLDT and treatment progress [J] Measuring method: the liver cirrhosis patients whose platelet measured value reduces less than 50K, and need to receive invasive operations

rhEPO- EPIAO & SEPO

Revenue of rhEPO, 2022H1

1

TOP 1 Market share

Two brands dominate **44.1%** market share, preside Top 1 position in terms of EPO market share

RMB million



rhEPO- Indications Contain Incremental Space



36%

Penetration rate

800K+ patients, 10% annual rate of growth



10%

Treatment rate

4 million+ CIA patients, Extremely low treatment rate of anemia



30%

Growth rate

Incremental space for penetration in low-tier market

CKD Related Increment

- Number of end-stage CKD patients reaches 3.5 million[1], 70% of dialysis patients suffer from anemia, while treatment rate < 40%
- 2021, NHC enhanced QC standards of renal anemia hemoglobin to 110g/L[2], then medication demands surged

CIA Related Increment

- 2019, CIA was listed in NRDL, departments coverage continue to grow
- "Practice Guidelines for Cancer Induced Anemia 2022" added 36000IU for primary recommendations for MDS[3]

Grassroots Level Market Increment

- NEDL stimulated low-tier medical institutions' adequate medication willingness
- EPIAO & SEPO cover 3 specifications in NEDL[4]

1.Data source: CNRDS 2020
2.NHC " 2021 Document for Improvement of Quality Control ([2021] no.51) "

3. MDS: .Myelodysplastic syndromes
4.Data source: on the 2018 National Essential Drug List, rhEPO covers 2000IU, 3000IU and 10000IU

Yisaipu- Explore to Reform

Revenue of Yisaipu, 2022H1

RMB million

Strategic Targets

RA：First-choice of combing with cDMRADs

AS：Preferred drug after diagnosed

Patient centered service

Optimize selling process, Strengthen patient management, excellent service support competitiveness

Develop new formulation

Sets with the injection have been launched; pre-filled injection may be launch in the end of 2022

Explore new collaborations

Collaborate with TCM rheumatism system, become prior treatment combined with TCM drugs ahead of other biopharmaceuticals

Grassroots sinking

Advance NEDL entry, promote rural revitalization projects, improve treatment level of grassroots, consolidate first-mover advantages

The first TNF-α inhibitor commercialized in China | Clinical experience surpass 16 years | Benefited 100K patients in total | Trained 16970 staff from fixed-point medical institutions | Cover 3200+ hospitals, including 900 plus county-level hospitals

Cipterbin- Break Bottleneck, Embrace Growth

Revenue of Cipterbin, 2022H1



1st

First-to-market domestic anti-Her2 Ab

National 863 Plan, National Great New Drug R&D Project, Priority Review Drug; Launched in 2020 and listed on the NRDL, Break the monopoly of imported products in anti-Her2 Ab market

11%

Improve ADCC responses

Fc portion modifications, antibody-dependent cell-medicated cytotoxicity of Inetetamab was enhanced 11%

60%

Extend half-life

Glycosylation modifications, the sialylation level+ 60%, half-life was extended, more significant drug effect

2 Impurity Multimer

Reduced immunogenicity

Optimized production technology, compared with trimer of trastuzumab, Inetetamab is safer in long-term clinical use due to its dimeric impurity multimer

Cipterbin- Break Bottleneck, Embrace Growth

Guideline	Release Subject	Release Time	Recommendation
Treatment Guidelines for Breast Cancer (2022)	CSCO	2022	**HER2-positive advanced breast cancer H treatment sensitive drugs recommendations**: Primary Recommendations: (1) THP(IA); (2) TXH (2A) Secondary Recommendations: (1) H+ chemotherapy (2A) chemotherapy includes: Taxanes, Vinorelbine, Capecitabine etc.; (2) Pyrotinib + Capecitabine (2A) --anti-HER2 mAb (H), including commercialized Trastuzumab, biosimilars, Inetetamab
Treatment Guidelines for Breast Cancer (2022)	NHC	2022	Other anti-HER2 drugs: Inetetamab combined with Capecitabine etc. chemotherapy can be considered as one of choice of anti-HER2 treatment for Trastuzumab non-resistant patients
Treatment Guidelines and Regulations for Breast Cancer	CACA	2021	HER2+ advanced first-line treatment recommendations: add Inetetamab combined with chemotherapy as a treatment option for Trastuzumab non-resistant patients
Administrative Methods for Clinical Applications of Anticancer Drugs	NHC	2020&2021	Add Inetetamab medication information and dosage regimen (biweekly or weekly)

All-round improvement of market coverage

Guideline position

Be improved from third-line to first-line treatment, significantly enlarge scale of the patients

Medical institutions coverage

The number of institutions increased from around 100 to over 1000

Patients coverage

Average monthly number of patients raised several times

Average DOT

Average DOT doubled

Business Ⅱ: Hair Healthcare

Mandi – Effective & Reliable Hair Product

Revenue of Mandi, 2022H1

RMB million

1

Top 1 Market Share

71.9% Market Share, secured top 1 minoxidil [1]



1. Data source：CPA

Mandi – 3 Channels Propel Sales Increase

Hospital

Revenue Increase:

~7%YOY

~16% of Revenue

200 plus personnel

~2000 hospitals

Layout privately-operated medical institutions, expand cooperations with chains

Retail Pharmacy

Revenue Increase:

~80%YOY

~31% of Revenue

100 plus personnel

90K Pharmacy, cover **90%** of **Top Chains**

Online Pharmacy License

国大药房 GuoDa Pharmacy
益丰大药房 Yifeng Pharmacy
大参林 DA SHEN LIN
北京同仁堂
老百姓大药房 LBX PHARMACY
海王星辰 NEP-STAR DRUG STORE

Ecommerce Platform

Revenue Increase:

~39%YOY

~53% of Revenue

Annually reached **20 million** plus people, **2 million** plus customers

New customer rate **~60%**

Female customer rate climbed continually

Ecommerce Platform	Rank	"618" Sales Achievement
天猫 Alibaba	1	Champion of OTC
京东 JD	4	4th of OTC
京东大药房 JD Pharmacy	1	No.1 of dermatologic OTC

Mandi- Build Product Matrix, Explore Vast Market

蔓迪

Mandi
60/90mL Male monthly course

Mandi White Bottle
30mL Female monthly course

Mandi Pro Portable Version
10mL, Equipped with diverse brushes



Mandi Foam
Be available soon, fill hair-loss market for sensitive hair skin population

Mandi Shampoo
Extend to scenes of life in terms of hair healthcare

Mandi Comb
Drug use & hair care integrated intelligent tool

Business Ⅲ: CDMO

CDMO- Global One-stop Service Platform

Revenue of CDMO Business, 2022H1

RMB million

- 20+ executing projects
- 100% achievement rate
- 100 million+ backlogs, YoY surged
- 1 NDA CDE accepted, The first customers' product succeeded to commercialization



CDMO- Competitive Edge

6	6 plants interconnected, flexible production system, serve the whole life cycle of drugs
>50	Experience of 50+ internal and external IND projects
15M	15 months from DNA to IND on average
0%	0% failure rate of IND application
24H	Rapid response to clients' demand within 24 hours

Type of Service

- mAb
- BsAb/ multispecific Ab
- Fusion protein
- Recombinant protein
- Neutralizing antibody
- Polypeptide
- Nucleic-acid drugs
- Cell therapy

CDMO- Six Global Plants

Group CDMO Map

- Devoted to R&D, Clinical Study and Commercialization Service in Regard to Biopharmaceuticals, Gene Therapy, Cell Therapy
- Committed to Providing Real One-stop Service for innovative drugs from DNA to Launch, Ensuring Smooth in All Key Milestones

Sirton, Italy

Formulations

Clients include Mylan, Sanofi and on

Guojian, Shanghai

Biopharmaceuticals

Depend on Sunshine Guojian professional biopharmaceuticals system, honored as Veteran in Biologics

Desen, Shenyang

Biopharmaceuticals

Initial stage 76K liters planned capacity, self-productivity of affinity resin & culture medium

Sunshine, Guangdong

Biopharmaceuticals CGT

Planned production lines contain formulation, stock solution, mRNA drugs and CGT mid-clinical R&D service

SIGO, Shanghai

Biopharmaceuticals

Planned biopharmaceuticals CDMO global R&D center, comprehensive incubators, imported formulation capacity

Sunshine, Suzhou

Biopharmaceuticals, Cell Therapy

Planned CDMO production lines complying with CH/US/EU GMP

Business Overview

Highlights

03

R&D

Q&A

Financial Review

Chairman, Director & CEO

Dr. Jing LOU

R&D Pipeline



5
Pre-clinical

7
IND& phase I

7
Phase II

9
Phase III &NDA &ANDA

5 BE

- Small molecule drugs
- Antibody-drugs
- Other drugs

2022 H1 R&D Progress

Nephrology

- **TPO-105 (Pediatric ITP)** phase III completed, NDA in preparations
- **TPO-106 (CLDT)** Phase Ib/II completed, prepare for Phase III
- **SSS06 long-acting EPO (Biweekly)** CKD phase III, prepare for CIA IND
- **RD01 long-acting EPO (Monthly)** prepare for phase III, prepare for orthopedics related IND
- **SSS17 HIF Inhibitor** phase Ib finished, get ready for phase II kick-off
- **Remitch (Narfuraphine hydrochloride orally disintegrating tablets)**

  On-site inspection approved



Candidates: 9

Auto-immune

- **301S TNFα-Fc R-protein** NMPA accepted for review
- **601A anti-VEGF mAb（BRVO）** Phase III conduct approved
- **608 anti-IL-17 mAb (PsO)** Phase II trial achieved the primary endpoint, prepare for Phase III
- **610 anti-IL-5 mAb** phase II enrollment, start co-design of phase II/III trials
- **611 anti-IL-4R mAb (AD)** phase Ib enrollment finished, **(CRS)** phase II/III IND application
- **613 anti-IL-1β mAb (AG Arthritis)** start phase Ib/II FPI



Candidates: 13

Dermatology

- **MN709 (Minoxidil foam)**）

NMPA accepted for review, prepare for on-site inspection



Oncology

- **617 anti-PSGL-1 mAb** IND approved
- **705 anti-PD1/HER2 BsAb** phase I enrollment
- **706 anti-PD1/PDL1 BsAb** prepare for phase I



Candidates: 10

Key Candidates: Nephrology Drug

Remitch (Narfuraphine hydrochloride orally disintegrating tablets)

First-line Drugs for Liver& Kidney Disease Pruritus in Japan Guidelines

- Uremic pruritus (UP) -2009
- Chronic Liver Disease Pruritus(CLD-aP) -2015
- Peritoneal dialysis Pruritus -2017

Kappa-opioid receptor agonist, avoid respiratory depression, constipation and addiction

First-to-market domestic drug targeting hemodialysis pruritus patients

Indications in Domestic Potential Market

Hemodialysis related pruritus
Antihistamines & hormones hard to alleviate itch

280K

Liver disease pruritus
Include liver cirrhosis, PD etc.

>1million

Exclusive product，Focus on Millions of Nephrology Patients' Clinical Demands

Irregular diagnosis and treat 01
Lack treatment guidelines, patient do not test, diagnose, treat correctly

Poor curative effect 02
Current treatment for pruritus do not consistent and adequate

Blank indications 03
No NMPA approved treatment, current drugs are used for off-label indications

Large side effects 04
Itch lead to drug abuse, co-infection, cardiovascular events etc.; addicted to opioid

Low quality of survival 05
60% of sleep disorders patients; possibility of depression doubled; death rate +24%

Key Candidates: Autoimmune Pipelines

Based on Clinical Demands for Autoimmune & Inflammation

01 **4.2%** prevalence of Asthma in the population aged 20 years and older in China, the number reached **45.7 million**;

---Massive CPH Study Launched on the Lancet in 2019 (Adults Lung Health Study in China)

02 **100 million approx.** COPD Patients **in China**

---COPD Prevalence and Risks Study in China Launched on the Lancet in 2018

03 **61.5 million** approx. AD patients in 2019, the number will increase to 65.9 million in 2030;

---Data source: Frost & Sullivan

04 **177 million approx.** Hyperuricaemia patients; **14.66 million approx.** Gout patients

--- "Guidelines for Hyperuricaemia & Gout (2019)"

Pipeline strategy:

Indications Coverage: RA、AS、PS	Pipeline Expansion, Construct FIC/BIC products	Pipelines Newly Indications Coverage AD, Chronic Rhinosinusitis, Asthma, AG Arthritis, …

Autoimmune Pipeline Launch Prospects:

Project	Indication	2023	2024	2025	2026	2027
608 (IL-17A)	PsO	NDA				
	SpA			NDA		
610 (IL-5)	Eosinophil asthma				NDA	
611 (IL-4R)	AD		NDA			
	Chronic Rhinosinusitis		NDA			
613 (IL-1β)	AG Arthritis			NDA		

Key Candidates: Anti-IL17A mAb (608)

608- Moderate-to-Severe Plaque Psoriasis

Brand-new Amino Acid Sequence Targeting IL-17A	Higher Drug Effect than Peers, Potential Best-in-class	High Incidence Rate, Huge Market Size
• 608 Ab adopts recombinant DNA technology and expresses in the CHO cells; • 608 Ab is a brand-new amino acid sequence targeting IL-17 • High expression level of cells	• The data of Phase II study showed that 80.6%, 89.3%, 91.4% of patients from 3 dose groups respectively all reach PASI 90[1] and sPGA0/1[2]; • 46.4%, 48.4%, 57.1% of patients could realize 100% improvement in the Psoriasis Area and Severity Index (PASI 100);	• **~0.47%** prevalence rate, 6.5-7 million /year PsO patients in China • 70%~80% of plaque psoriasis among all PsO, exist huge market potential and the global market share increased by years; • Anti-IL-17 mAb shows high efficacy for PsO patients, worldwide status improved by years

608 PsO Progress Rank No.3 in China

Product	Target	Company	Indication	Pre-or IND	Ⅰ	Ⅱ	Ⅲ	NDA/ Launch
SHR1314	IL-17A	Hengrui	PsO					
GR1501	IL-17A	Zhixiang	PsO					
SSGJ-608	**IL-17A**	**Sunshine Guojian**	**PsO**					
JS005	IL-17A	Junshi	PsO					
LZM012	IL-17A/F	Livzon	PsO					
HB0017	IL-17	Huabo	PsO					

Global sales of biopharmaceuticals for PsO



Data source： Annual reports

1. Psoriasis Area and Severity Index improved by 90%
2. According to Physician's Global Assessment, Psoriasis was fully or nearly fully eliminated

Key Candidates: Anti-IL5 mAb (610)

610- Eosinophil Asthma

Brand-new mAb Targeting IL-5, Variable Region Sequences

- Adopt recombinant DNA technology, new sequences recombinant IgG1 mAb developed independently;
- Combined with IL-5 directly to block action with the α chain receptor on EOS surface, inhibit eosinophilic airway inflammation response, reduce acute episode risks

Good Safety and Significant Drug Effect

- Drug effectiveness: one dose every 4 weeks, indicator showed significant improvement;
- Good safety, long half-life, significant linear relation between exposure and dose

High Incidence Rate, Huge Market Size

- The article[1] launch on the Lancet in 2019 illustrates, **4.2%** prevalence rate of Asthma in the population aged 20 years and older in China, the number reached **45.7 million,** greatly exceed past estimation;
- Biopharmaceuticals for asthma grew successively in the past years

The First IL-5 mAb IND in China, Progress Rank No.1

Product	Target	Company	Indication	IND	Ⅰa	Ⅰb	Ⅱ	Ⅲ	NDA/ Launch
SSGJ-610	IL-5	Sunshine Guojian	Eosinophil Asthma						
SHR-1703	IL-5	Hengrui	Eosinophil Asthma						

Global sales of biopharmaceuticals for asthma



Data source: Annual reports

1. "Study for Prevalence, Risks and Diseases Management of Adults Asthma in China"

Key Candidates: Anti-IL4R mAb (611)

611-Moderate-to-Severe Atopic Dermatitis

Brand-new Amino Acid Sequence Targeting IL-4Rα

- Recombinant humanized IgG4 mAb;
- Targeting IL-4Rα, block signaling mechanisms of IL-4/IL-13, reduce Th2 immune response, recover the balance of immune system;
- Both IND in China and U.S.

Good Safety and Significant Drug Effect

- Good safety and tolerance, especially incidence rate of conjunctivitis far lower than Dupilumab;
- Significant drug effect: EASI Ratings, AD BSA involvement, NRS (pruritus) indicated significant improvement

High Incidence Rate, Huge Market Size

- **Worldwide:** High incidence rate: 20% prevalence rate of AD among children, 2%-10% rate of AD among adults;
- **China:** 12.94% prevalence rate of AD among children (1-7 years old), 30.48% prevalence rate of AD among babies (<1 year old);
- First-line therapy TCS may induce adverse effect after long-term use, while 30~50% possibilities of poor efficacy;
- AD induced pruritus influence quality of life heavily;

611 AD Progress Rank No.3 in China

Product	Target	Company	Indication	IND	Ⅰ	Ⅱ	Ⅲ	NDA/ Launch
CM310	IL-4R	Keymed	AD					
CBP-201	IL-4R	Connect	AD					
SSGJ-611	**IL-4R**	**Sunshine Guojian**	**AD**					
AK120	IL-4R	Akeso	AD					
GR1802	IL-4R	Zhixiang	AD					
QX005N	IL-4R	Quanxin	AD					
MG-K10	IL-4R	Maiji	AD					
SHR-1819	IL-4R	Hengrui	AD					

Global sales of Dupilumab



Data source： Annual reports

1. EASI: Eczema Area and Severity Index, BSA: Body Surface Area, NRS: numerical rating scale

Key Candidates: Anti-IL1β mAb (613)

613- Acute Gout Arthritis

Brand-new mAb Targeting IL-1β

- anti-IL1β humanized mAb adopt DNA recombinant technology, and express in the CHO cells;
- IL-1β is a major mediator of acute gout arthritis inflammation, targeting IL-1β treatment is efficient for acute gout arthritis

Good Safety, Significant PK Linear Relation

- Study on Chinese subjects demonstrate outstanding safety and tolerance
- PK traits: long half-life, exposure and dose indicated significant linear relation;
- Current data showed no ADA positive;
- Non-clinical & clinical results indicated similarities with Canakinumab

High Incidence Rate, Huge Clinical Demands

- **Worldwide:** the research based on Asian, European, and North American population illustrates, 0.6 to 2.9/1K person /year incidence rate, 0.68%-3.90% adults prevalence ratio;
- **China:** 1%~3% prevalence, grow rapidly at 9.7%/year; most gout patients suffer from acute episode repeatedly;
- ACR, EULAR and China Guideline: patients with repeated episode or refractory AG could consider IL-1 receptor treatment

Attractive Market Competition Structure, 613 Progress Rank No.3

Product	Target	Company	Indication	IND	Ⅰ	Ⅱ	Ⅲ
Jinna mAb	IL-1β	Changchun Jinsai	Acute gout arthritis				
SSGJ-613	**IL-1β**	**Sunshine Guojian**	**Acute gout arthritis**				
Recombinant IL-1 receptor antagonist	IL-1β	Jiaochen	Gout arthritis (interval)				

Global sales of Canakinumab



Data source: Annual reports

International Cooperation

International R&D Collaboration

verseau Massachusetts U.S.

- Select candidates in tumor immunotherapy, 3SBio is responsible for commercialization in Greater China[1]
- PSGL-1 (617) IND approved

NUMAB Drug Innovators Zurich Switzerland

- Select NM28 as the initial authorized product (NM28 is the best potential CD3 T-cell engager targeting MSLN for mesothelioma treatment

License-in

Sensorion France

- Acquired the right of first refusal of 4 product candidates in greater China from Sensorion

COSMO Italy

- partnered with Cosmo and licensed in the exclusive right of Winlevi® cream to treat acne in Greater China and the right of first refusal of Breezula® solution to treat alopecia

International Registration /Clinical Trial

Commercialized products registered abroad

- TPO was acquired launching license from 9 countries while registered in over 10 countries
- EPIAO was acquired launching license from 23 countries while registered in 6 countries
- Yisaipu was acquired launching license from 15 countries and registered among various countries

Independent R&D innovative products conducted international clinical trials

- 609A、611、705、706 products are conducted IND/ clinical study in both China and U.S.

License-out

- **609A anti-PD1 mAb:** The global development and commercialization right of 609A for its Syncrovax™ (specific therapy) were authorized to Syncromune Inc. 3Sbio has received an upfront payment and receive future regulatory and sales milestone payments and other incentives, the amount is more than 1 billion in total
- **Cipterbin:** The ADC development and global commercialized rights of Cipterbin were authorized to Kelingyuan, total amount of the deal peaked at 1.025 billion RMB

1. Taiwan, Hongkong, and Macao markets are included

R&D Center and Platform

Four Centers, Five Platforms --Cover All-process of R&D, Registration, Clinical trials, Manufacture

Shenyang center

Shanghai center

Shenzhen center

Hangzhou center

BsAb & Multispecific Ab Platform

Multifunctional
New mechanism
Distinct druggability, easy to product （CLF2 BsAb Platform）

Multifunctional Fc Protein Platform

Discover new function based on new mechanism
Diversified forms

Ab Maturity and Optimization Platform

Humanized
Improve physicochemical properties
Mature affinity
Function expansion and optimization

Ab Selection Platform

Facilitate new targets R&D
Convenient, fast, costs-controllable R&D

Pre-clinical Animal Drug Effect Platform

Convenient, fast, costs-controllable
On-demand design for explore new mechanism
Mouse, rat, rabbit etc. multi-species project design

Highlights

Business Overview

04

Financial Review

Q&A

R&D

Chief Financial Officer

Mr. Fei WANG

Financial Analysis

Revenue



Gross Profit



NI Attributable to Parent



NORM NI Attributable to Parent



Expense Management

Selling and Distribution Expenses

RMB billion



S&D Ratio	36.7%	36.1%	36.4%	37.1%	37.3%

R&D Costs

RMB mllion



R&D Ratio	9.9%	10.6%	11.8%	11.1%	9.5%

Administrative Expenses

RMB million



AE Ratio	12.7%	8.1%	5.8%	5.4%	6.3%

Total Assets & Debt

Total Assets

RMB billion



Net Assets

RMB billion



Debt Asset Ratio



Sublime CF Condition, Sufficient FCF

OCF

RMB billion



Cash Equivalents (Financing Proceeds Included)

RMB billion



Extremely Attractive Earnings

EPS (HKD)



ROE



Business Overview

Financial Review

R&D

Management

Highlights

05

Q&A

THANKS

3SBio Inc. (1530.HK)
Investor Relations
ir@3sbio.com

珍 爱 生 命 · 关 注 生 存 · 创 造 生 活

CHERISH LIFE CARE FOR LIFE CREATE LIFE